Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...

Dr. Albert Bourla, Chairman and CEO of Pfizer: “We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved ...

Pfizer (PFE), and Johnson & Johnson (JNJ) secured spots on China's first innovative drug catalog for private insurance, ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the ...

Second-quarter 2024 Cost of Sales(4) as a percentage of revenues was relatively flat compared with the prior-year quarter, and reflects favorable changes in sales mix, primarily driven by lower sales ...

Pfizer on Tuesday reported third-quarter revenue and adjusted profit that blew past expectations as the company's Covid vaccine and antiviral pill Paxlovid helped boost sales. The pharmaceutical giant ...

Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis Sangamo is eligible to earn from Pfizer up to $220 million in milestone payments ...

* Indicates calculation not meaningful or results are greater than 100%. First-quarter 2025 Cost of Sales (2) as a percentage of revenues decreased by 2.0 percentage points compared to the prior-year ...